Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.

@article{Vijmasi2014TopicalAO,
  title={Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.},
  author={Trinka Vijmasi and Feeling Y.-T. Chen and Suganthalakshmi Balasubbu and Marianne Gallup and Robert L. McKown and Gordon W. Laurie and Nancy A McNamara},
  journal={Investigative ophthalmology & visual science},
  year={2014},
  volume={55 8},
  pages={
          5401-9
        }
}
PURPOSE Lacritin is a tear glycoprotein with prosecretory, prosurvival, and mitogenic properties. We examined lacritin levels in the tears of Sjögren's syndrome (SS) patients and explored the therapeutic potential of topical lacritin for the treatment of keratoconjunctivitis sicca. METHODS Tears from healthy controls (n = 14) and SS patients (n = 15) were assayed for lacritin using a C-terminal antibody. In a paired-eye study, autoimmune regulator (Aire) knockout (KO) mice (n = 7) were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…